Johnson & Johnson (NYSE:JNJ), (BNTX) - Johnson & Johnson's Vaccine Gets Unanimous Backing Of FDA Panel, Emergency-Use Authorization Soon To Come

Moderna Inc (NASDAQ: MRNA) and
Pfizer Inc. (NYSE: PFE)-
BioNTech SE – ADR (NASDAQ: BNTX) for their vaccine candidates.
Moderna and Pfizer-BioNTech received authorizations for their vaccine candidates in December.
Unlike the messenger RNA vaccines of Moderna and Pfizer-BioNTech, J&J's vaccine candidate uses a single-dose regimen and is an experimental viral vector vaccine that uses a weakened form of adenovirus to transport genetic material to trigger immune response.
J&J's vaccine candidate can remain stable for two years at -20 degrees Celsius, at least three months of which can be at temperatures of 2-8 degrees Celsius. The vaccines from Moderna and Pfizer, on the other hand, require cold-chain logistics to stay effective.

Related Keywords

Paul Stoffels ,Janet Woodcock ,Us Centers For Disease ,World Health Organization ,Drug Administration ,Pfizer ,Pfizer Inc ,Moderna Inc ,Prevention Advisory Committee On Immunization Practices ,Products Advisory Committee ,Acting Commissioner Janet Woodcock ,Related Biological Products Advisory ,Disease Control ,Advisory Committee ,Immunization Practices ,Daily Biotech Pulse ,Regulatory Setback For ,ஜேனட் மரக்கட்டை ,எங்களுக்கு மையங்கள் க்கு நோய் ,உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,ஃபைசர் ,ஃபைசர் இன்க் ,மாடர்னா இன்க் ,நடிப்பு ஆணையர் ஜேனட் மரக்கட்டை ,நோய் கட்டுப்பாடு ,நோய்த்தடுப்பு ப்ர்யாக்டிஸஸ் ,தினசரி பயோடெக் துடிப்பு ,